Expression of Lewis X is associated with poor prognosis in triple-negative breast cancer

Am J Clin Pathol. 2013 Jun;139(6):746-53. doi: 10.1309/AJCP2E6QNDIDPTTC.


The Lewis X (Le(X)) antigen is a prognostic marker in certain solid tumors and has been proposed as a therapeutic target. Immunohistochemical analyses were performed to retrospectively examine the prognostic impact of Le(X) expression in 158 patients with triple-negative breast cancer (TNBC). Twenty-three (14.5%) patients were Le(X)-positive. Multivariate analysis showed that Le(X) positivity was an independent poor prognostic factor for recurrence-free survival (RFS) and overall survival (OS) (P = .037 and P = .024, respectively). Le(X) expression was a prognostic factor for survival in stage I/II and stage III TNBCs. Subgroup analysis according to age showed that Le(X) positivity was only associated with poor RFS and OS in younger patients with TNBC (age < 50 years) (P < .001 and P < .001, respectively). Our results suggest that Le(X) expression is an independent prognostic factor for RFS and OS in younger patients with TNBC.

Keywords: Lewis X; Prognosis; Triple-negative breast cancer.

MeSH terms

  • Biomarkers, Tumor / biosynthesis*
  • Breast Neoplasms / immunology*
  • Breast Neoplasms / mortality*
  • Breast Neoplasms / pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Lewis Blood Group Antigens / immunology*
  • Lewis X Antigen / biosynthesis*
  • Middle Aged
  • Prognosis
  • Retrospective Studies


  • Biomarkers, Tumor
  • Lewis Blood Group Antigens
  • Lewis X Antigen